Erythromycin (oral): Difference between revisions
| Line 32: | Line 32: | ||
'''| [[Erythromycin labels and packages|Labels and Packages]]''' | '''| [[Erythromycin labels and packages|Labels and Packages]]''' | ||
==Mechanism of | == Mechanism of action == | ||
Erythromycin displays [[bacteriostatic]] activity or inhibits growth of bacteria, especially at higher concentrations,<ref name="ReferenceA">Katzung PHARMACOLOGY, 9e Section VIII. Chemotherapeutic Drugs Chapter 44. | |||
Chloramphenicol, Tetracyclines, Macrolides, Clindamycin, & Streptogramins</ref> but the mechanism is not fully understood. By binding to the 50s subunit of the bacterial 70s [[rRNA]] complex, protein synthesis and subsequent structure and function processes critical for life or replication are inhibited.<ref name="ReferenceA"/> Erythromycin interferes with [[aminoacyl translocation]], preventing the transfer of the [[tRNA]] bound at the [[A site]] of the rRNA complex to the [[P site]] of the rRNA complex. Without this translocation, the A site remains occupied and, thus, the addition of an incoming tRNA and its attached [[amino acid]] to the nascent [[polypeptide]] chain is inhibited. This interferes with the production of functionally useful proteins, which is the basis of this antimicrobial action. | |||
==References== | ==References== | ||
Revision as of 22:45, 8 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Overview
Erythromycin is a macrolide antibiotic that has an antimicrobial spectrum similar to or slightly wider than that of penicillin, and is often prescribed for people who have an allergy to penicillins. For respiratory tract infections, it has better coverage of atypical organisms, including Mycoplasma and legionellosis. It was first marketed by Eli Lilly and Company, and it is today commonly known as EES (erythromycin ethylsuccinate, an ester prodrug that is commonly administered). It is also occasionally used as a prokinetic agent.
In structure, this macrocyclic compound contains a 14-membered lactone ring with ten asymmetric centers and two sugars (L-cladinose and D-desosamine), making it a compound very difficult to produce via synthetic methods.
Erythromycin is produced from a strain of the actinomycete Saccharopolyspora erythraea.
Category
Macrolide
US Brand Names
AKNE-MYCIN®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages
Mechanism of action
Erythromycin displays bacteriostatic activity or inhibits growth of bacteria, especially at higher concentrations,[1] but the mechanism is not fully understood. By binding to the 50s subunit of the bacterial 70s rRNA complex, protein synthesis and subsequent structure and function processes critical for life or replication are inhibited.[1] Erythromycin interferes with aminoacyl translocation, preventing the transfer of the tRNA bound at the A site of the rRNA complex to the P site of the rRNA complex. Without this translocation, the A site remains occupied and, thus, the addition of an incoming tRNA and its attached amino acid to the nascent polypeptide chain is inhibited. This interferes with the production of functionally useful proteins, which is the basis of this antimicrobial action.